MÉTHODE POUR DÉTECTER DE MANIÈRE PRÉCOCE UNE INSUFFISANCE RÉNALE AIGUË CHEZ DES PATIENTS CRITIQUES, FAISANT INTERVENIR LE FACTEUR DE CROISSANCE DES FIBROBLASTES 23, LE GÈNE KLOTHO ET L'ÉRYTHROPOÏÉTINE EN TANT QUE BIOMARQUEURS
The invention relates to an ex vivo method for the early detection of acute kidney injury in critical patients, comprising the use of measurements of fibroblast growth factor 23 (FGF23), klotho (KL) and erythropoietin (EPO) as biomarkers, where such measurements are obtained from a venous blood sample or urine, and allow the following factors to be calculated: 1 = ([FGF23]p x [EPO]p)； 2 = ([FGF23]p / [Klotho]p)； 3 = ([EPO]p) / [Klotho]p)； 4 = (([FGF23]p x [EPO]p) / [Klotho]p)； where [X]p is the measurement of the plasma level of X and X is selected from fibroblast growth factor 23 (FGF23), klotho (KL) and erythropoietin (EPO). If the value of the indicator 1, 2, 3, 4 or two or more thereof, is higher than, or equal to, a cut-off point (10 U) which allows identification of patients with and without AKL with a high level of sensitivity/specificity, then a high probability of presence/development of AKI is confirmed, and measures can be taken for patients with AKI. If the indicator value 1, 2, 3, 4 or two or more thereof is lower than the previously mentioned cut-off point, then the probability of presence/development of AKI is low and standard treatment can be carried out, that is, with use of endovenous solutions, prevention of the use of nephrotoxins, use of renal replacement therapy in severe AKI, inter alia.
